SCHEMBL31200587

SCHEMBL31200587

CC(C)(C)OC(=O)N[C@@H]1C[C@@H](OCc2ccccc2)C[C@H]1O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KDM1A O60341 2/20 0.44
MAOB P27338 1/20 0.44
KLK5 Q9Y337 5/20 0.43
KLK7 P49862 4/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA7 P43166 1/20 0.43
CA14 Q9ULX7 1/20 0.43
PDE4B Q07343 1/20 0.41
CTSL P07711 1/20 0.41
SYK P43405 1/20 0.41
CPB1 P15086 1/20 0.41
PPARA Q07869 1/20 0.41
ABCB1 P08183 1/20 0.40
AKT1 P31749 2/20 0.39
EPHX2 P34913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31200867 1.00 KMT2A (0.47) KMT2AL3MBTL1KDM1AMAOBKLK5
SCHEMBL31614132 1.00 KMT2A (0.47) KMT2AL3MBTL1KDM1AMAOBKLK5
SCHEMBL3830180 0.85 KMT2A (0.60) KMT2AL3MBTL1KDM1AMAOBKLK5
SCHEMBL9430749 0.85 KMT2A (0.60) KMT2AL3MBTL1KDM1AMAOBKLK5
SCHEMBL3830184 0.85 KMT2A (0.60) KMT2AL3MBTL1KDM1AMAOBKLK5
SCHEMBL23185762 0.84 KMT2A (0.50) KMT2AL3MBTL1KDM1AMAOBKLK5
SCHEMBL30143734 0.84 KMT2A (0.50) KMT2AL3MBTL1KDM1AMAOBKLK5
SCHEMBL31470310 0.84 KMT2A (0.52) KMT2AL3MBTL1KDM1AMAOBKLK5
SCHEMBL31200784 0.83 KMT2A (0.43) KMT2AL3MBTL1KDM1AMAOBKLK5
SCHEMBL19863570 0.83 KMT2A (0.47) KMT2AL3MBTL1KDM1AMAOBKLK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680601-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES Sanofi (FR) 2026-01-21 EP disclosed
US-20240360151-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES SANOFI (FR) 2024-10-31 US disclosed
WO-2024188994-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES SANOFI (FR) 2024-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360151-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES NLRP3, NOD1, NLRP1 KMT2A 4589/4885L3MBTL1 3872/4885KDM1A 3176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.